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Spatial inequalities in colorectal and breast cancer survival: premature 
deaths and associated factors 
Susanna M Cramb, Kerrie L Mengersen, Gavin Turrell, Peter D Baade 
 
Abstract 
This study examines the influence of cancer stage, distance to treatment facilities and area 
disadvantage on breast and colorectal cancer spatial survival inequalities.  We also estimate 
the number of premature deaths after adjusting for cancer stage to quantify the impact of 
spatial survival inequalities. Population-based descriptive study of residents aged <90 years 
in Queensland, Australia diagnosed with primary invasive breast (25,202 females) or 
colorectal (14,690 males, 11,700 females) cancers during 1996-2007. Bayesian hierarchical 
models explored relative survival inequalities across 478 regions. Cancer stage and 
disadvantage explained the spatial inequalities in breast cancer survival, however spatial 
inequalities in colorectal cancer survival persisted after adjustment. Of the 6,019 colorectal 
cancer deaths within 5 years of diagnosis, 470 (8%) were associated with spatial inequalities 
in non-diagnostic factors, i.e.  factors beyond cancer stage at diagnosis. For breast cancers, of 
2,412 deaths, 170 (7%) were related to spatial inequalities in non-diagnostic factors. 
Quantifying premature deaths can increase incentive for action to reduce these spatial 
inequalities. 
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Background 
Worldwide, breast cancer is the most common cancer in women, while colorectal cancer is 
the second most commonly diagnosed among women, and third most common among men 
(Ferlay et al., 2010).  In developed nations, including Australia, survival for both these 
cancers has improved over recent decades (Australian Institute of Health and Welfare and 
Cancer Australia & Australasian Association of Cancer Registries, 2008), with Australia 
having one of the highest survival rates in the world (Coleman et al., 2011).   
 
However, the improvement in survival has not been observed equally across all population 
subgroups. Inequalities for both breast and colorectal cancer survival have been reported by 
deprivation and differences in health care access (Du et al., 2011; McKenzie et al., 2011). 
Within Australia, poorer survival has been observed for those in areas of greater socio-
economic disadvantage, geographic remoteness and, for rectal cancer, further distance to 
radiotherapy facilities (Australian Institute of Health and Welfare and Cancer Australia & 
Australasian Association of Cancer Registries, 2008; Baade et al., 2011b; Cramb et al., 
2011).  
 
The quality of patient management can be gauged by survival (Yu et al., 2004). The 
prognosis for breast and colorectal cancer depends in large part on the stage of disease at 
diagnosis (Schottenfeld and Fraumeni Jr, 2006), which may vary geographically (Tian et al., 
2012; Tian et al., 2011).  Beyond that, the outcome depends on other non-diagnostic factors 
such as treatment, rehabilitation, environmental factors such as area disadvantage, and patient 
characteristics including comorbidities (Yu et al., 2005a), all of which could potentially 
contribute  to geographical variation in cancer survival. Throughout this paper we use the 
term “non-diagnostic” to encompass these other factors.  
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Since only a few population-based cancer registries collect stage information, not many 
studies have been able to separate the effect of diagnostic from other factors on geographic 
inequalities in cancer survival on a population basis. In New South Wales (NSW), Australia, 
it was found that adjusting for stage did not reduce the survival differential for colorectal 
cancer (Yu et al., 2005a). However, in Italy, stage at diagnosis explained most of the 
colorectal cancer survival inequalities between Northern and Southern areas, while treatment 
had a minimal role (Fusco et al., 2010). In England, stage at diagnosis and deprivation were 
important causes of breast cancer survival inequalities (Davies et al., 2010).  
 
However these previous studies have used relatively large geographical regions, which 
reduce the ability to measure spatial variation and can limit interpretation because of the 
greater heterogeneity within those regions. In contrast, inequalities in cancer survival at the 
small-area level have rarely been examined, typically due to difficulties associated with 
sparse data in small geographical areas and in accounting for the spatial correlation between 
neighboring areas (Wakefield and Elliott, 1999). Bayesian hierarchical methods overcome 
both problems by incorporating information from neighboring areas for each estimate, 
producing more reliable small-area estimates (Carlin and Xia, 1999).  
 
Spatial survival analysis is an emerging field. Most analyses have focused on cause-specific 
survival (Henry et al., 2009; Huang et al., 2007; Wan et al., 2012). We chose to instead use 
Bayesian hierarchical methods to model relative survival (Fairley et al., 2008; Saez et al., 
2012), where cancer patient mortality is compared against mortality in the population of 
similar age, sex and time period. Our focus was on comparing survival up to 5-years after 
diagnosis. 
4 
 
 
To quantify the impact of spatial inequalities in cancer survival, previous studies have 
calculated the number of deaths that could have been prevented within a given timeframe if 
there was no systematic regional variation in survival (Dickman et al., 1997; Yu et al., 2004). 
These estimates of avoidable premature deaths provide an objective measure by which to 
advocate for resource allocation and establish health priorities (Yu et al., 2004). 
 
This study has two aims: 
1. To examine the influence of cancer stage at diagnosis, distance to treatment facilities 
and area-disadvantage on spatial survival inequalities for breast and colorectal cancer, 
and 
2. To estimate the number of premature deaths due to non-diagnostic-related spatial 
survival inequalities after adjusting for cancer stage at diagnosis. 
 
Methods 
Data 
Study cohort 
Data on colorectal  (ICD-O3 C18-C20,C218) and breast  (ICD-O3 C50) cancers diagnosed in 
Queensland during 1996 to 2007 were obtained from the Queensland Cancer Registry (QCR) 
following approval from Queensland Health (Ethics approval number: HREC/09/QHC/25). 
Due to small numbers, male breast cancers were excluded from analysis. The QCR is a 
population-based registry which has been in operation since 1982 (Queensland Cancer 
Registry, 2010), and covers a population of 4.2 million (in 2007) (Australian Bureau of 
Statistics, 2008b). Notification of cancer (excluding non-melanoma skin cancer) to the QCR 
is required by law (Queensland Cancer Registry, 2010). Data quality is high, as evidenced by 
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the high percentage of cases diagnosed with histological verification (92.1%) and low 
percentage of cases diagnosed by death certificate only (1.4%) in 2007. 
 
The survival analysis included the first occurrence of a primary colorectal or breast cancer in 
individuals aged less than 90 years at diagnosis. Cases were excluded if they lacked age or 
SLA of residence information, were identified at autopsy, notified via death certificate only 
or had a survival time of less than one day. All cases were followed until 31
st
 December 
2007. 
 
Stage at diagnosis 
Colorectal cancer stage was extracted from pathology records held by the QCR (Krnjacki et 
al., 2008) and then classified based on the Dukes staging system (Haq et al., 2009). To 
increase accuracy (Krnjacki et al., 2008) and reduce problems with sparse data, stage was 
grouped into three categories: early (localized/non-localized), advanced (regional/distant) and 
unknown.  
 
The QCR does not collect detailed information about breast cancer stage at diagnosis. 
However, consistent with recent reports (Baade et al., 2011c; Krnjacki et al., 2008; Youlden 
et al., 2009), “Early” breast cancer was defined as ≤20 mm diameter with no evidence of 
lymph node involvement or distant metastases (stage I). Although it was unlikely these cases 
had metastasized, this could not be established.  There was insufficient detail to distinguish 
between stages II, III or IV, so these were collectively categorized as “Advanced” breast 
cancers. Cancers diagnosed as a result of metastatic disease were included in this category.  
The “Unknown” category included those with unknown tumor size or unknown lymph node 
status if the tumor size was ≤ 20mm.    
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Geographical location 
Statistical Local Areas (SLAs) were used as the region of analysis. Cancer incidence data 
across all years were mapped to the 2006 SLA boundaries based on suburb and postcode of 
residence prior to data extraction. In 2006 Queensland had 478 SLAs, which covered the 
State without gap or overlap, with a median population of 5,810 (range: 7 to 77,523). 
Based on their SLA of residence, each patient was assigned to a quintile of area disadvantage 
based on the Australian Bureau of Statistics (ABS) Socioeconomic Indexes for Areas Index 
of Relative Disadvantage (SEIFA-IRSD) (Australian Bureau of Statistics, 2008a).  
 
Distance to treatment 
The distance to the closest radiation facility was calculated by geocoding the location of all 
radiation facilities in Queensland, and the centroid of each SLA at diagnosis. A custom GIS 
application was used to calculate the shortest travelling time by road from each SLA centroid 
to the closest radiation facility by each year to account for increasing coverage of the 
radiation facilities over time. Radiotherapy facilities are only located in larger cities. By the 
end of 2007 there were a total of 4 public and 5 private radiotherapy facilities in Queensland. 
Five (3 public and 2 private) were located in Brisbane, three additional private facilities were 
located within a 125 km radius of Brisbane, and another public facility in Townsville (1,360 
km north of Brisbane). 
 
Distance was classified into three categories based on practical considerations to improve the 
interpretation of estimates: < 2 hours (return travel within one day), 2-6 hours (one full day of 
travelling) and > 6 hours (more than one day of travel with overnight accommodation 
required). 
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Survival estimates 
Unadjusted relative survival estimates were calculated using actuarial (life table) methods. 
Expected survival was estimated using the Ederer II method (Ederer and Heise, 1959)  with 
the Stata macro strs, based on Queensland life tables generated from mortality data obtained 
from the ABS. The population mortality was calculated by each SLA, gender and 5-year age 
group (to ages 90+). Estimates were calculated for two aggregated time periods for greater 
stability; 1997-2002 and 2003-2007, and then applied to each year within the appropriate 
time period. 
 
Survival estimates were derived using period analysis, in which survival is calculated using 
patients alive during the time period of interest (Brenner and Hakulinen, 2009). Since the 
focus was on estimating survival inequalities up to 5 years after diagnosis, each individual’s 
follow-up time was censored at 5 years after diagnosis.  
 
The expected number of deaths, person time at risk, and deaths in the interval was calculated 
for each individual, then aggregated over each combination of SLA (1 to 478 areas), follow-
up period (1 to 5 years after diagnosis) and covariates consisting of age at diagnosis (0-49, 
50-69 and 70-89 years), stage at diagnosis (early, advanced and unknown), distance to 
treatment facilities (<2 hours, 2 – 6 hours and 6+ hours) and for colorectal cancer, gender 
(male and female). Since there was an exact concordance between SLA and area 
disadvantage, aggregating by area disadvantage was not required. 
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Statistical model 
The Bayesian spatial survival model adopted for this analysis assumed the hazards were 
constant within pre-specified follow-up time intervals, and was based on the model described 
by Fairley et al (Fairley et al., 2008), 
                   
             
                                                  [1]          
where     , the observed deaths in the k
th
 stratum, t
th
 follow-up interval and i
th
 SLA  follows a 
Poisson distribution with mean     ,           
   is the modeled number of excess deaths 
with     
  representing the expected number of deaths due to other causes,      is person-time 
at risk,    is an intercept which varies by time,    is the coefficient of the predictor variable 
vector x (representing broad age at diagnosis groups, distance to treatment, area 
disadvantage, stage and, for colorectal cancer, gender),    is the spatial random effects for the 
i
th
 SLA and    is the unstructured random effects. Non-informative normal distributions were 
used as priors on the parameters, apart from    which was assigned an intrinsic conditional 
autoregressive (CAR) prior. Refer to the Appendix for further information on the prior 
distributions. 
 
The effects of age, stage, area disadvantage and distance to treatment were explored by 
including various combinations in models. The Deviance Information Criterion (DIC)  
(Spiegelhalter et al., 2002) was used to compare model goodness of fit, with lower values 
indicating a better model.  
 
The exponential of the parameter estimates are the excess hazard ratios, also called relative 
excess risks (RERs).  The RERs for estimates of the impact of the covariates of interest were 
calculated as exp(β) from Equation (1), and were in comparison to the baseline level of the 
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covariate. For the estimates in each SLA the RER was calculated as exp(     ), and 
provided an estimate of the excess risk of death in that SLA against the Queensland average 
excess risk of death.  
 
The models were analyzed using Markov chain Monte Carlo (MCMC), via WinBUGS 
(Imperial College and Medical Research Council, UK), interfaced with Stata  (StataCorp, 
Texas) (Thompson et al., 2006). A burn-in period of 250,000 iterations was discarded, and a 
further 100,000 iterations monitored (with every 10
th
 iteration kept). A global clustering test 
(Tango’s Maximized Excess Events Test (MEET) (Tango, 2000)) was used to determine if 
there was significant variation in the RER estimates across the SLAs. This method was 
preferred over other global clustering tests as it has been shown to effectively identify overall 
spatial variation across a variety of datasets (Kulldorff et al., 2006). 
 
The 80% credible interval (CrI) was provided for all posterior distributions, as this is 
considered to provide sufficient coverage (Richardson et al., 2004). For non-Bayesian 
analyses we used the standard 95% confidence interval (CI). 
 
The probability of a specific estimate being higher than the estimate in the previous category 
can be used as an alternative to the credible interval when comparing categories. High values 
(above 80% when expressed as a percentage, consistent with 80% credible intervals) indicate 
the estimate is likely to be above the former category. This was calculated as the percentage 
of MCMC iterations for a given estimate that were higher than the preceding stratum-specific 
estimate, and was provided for RER and the proportion of premature deaths. 
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Premature deaths 
In calculating the number of premature deaths, we set the optimum benchmark for survival to 
be equal to the 20
th
 centile RER of ranked SLAs, consistent with other published results (Yu 
et al., 2004). To exclude the diagnostic component of survival, and quantify only the non-
diagnostic survival component, we used results from the Bayesian spatial survival model 
(equation 1) that included stage, along with age and gender. Areas with an RER below the 
20
th
 centile were excluded from the calculations of observed deaths (     , expected deaths 
due to other causes (    
 ) and person-time at risk (      to avoid theoretically increasing their 
risk of death to the 20
th
 centile. 
 
There were three parameters required to calculate premature deaths resulting from spatial 
inequalities: observed excess deaths, optimum excess deaths and the spatial fraction.  
 
Observed excess deaths 
In relative survival the ‘excess deaths’ are the deaths considered to be caused by the cancer. 
Instead of counting a death if the death certificate recorded it as a cancer death (as in cause-
specific survival), all deaths among cancer patients are compared against the mortality that 
would be expected among people of similar age, gender, SLA of residence and broad time 
period. This prevents bias due to inaccuracies in coding deaths. 
 
The modeled number of excess deaths within five years of diagnosis is calculated as      
    
  (from equation 1). The observed number of excess deaths within five years of diagnosis 
at each stratum is: 
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   ∑∑          
  
 
 
   
                                                                          
  
 
where dkti is the number of observed deaths from any cause in the k
th
 strata, t
th
 follow-up 
period, and i
th
 SLA, and     
  represents the number of expected deaths due to other causes 
estimated by applying the population mortality rates to the study cohort.   
 
Optimum excess deaths 
The optimum number of excess deaths is the number of deaths that would be observed within 
five years of diagnosis if there were no inequalities in non-diagnostic factors. This was 
calculated by multiplying the excess mortality rate at the 20
th
 centile by person-time at risk, 
separately for each stratum and follow-up interval and then summed over the follow-up 
intervals: 
 
     ∑                                                                     
 
   
 
where          were the random effect values corresponding to the lowest 20
th
 centile of 
relative excess risk across all the SLAs, and other variables were as described in equation 1.  
 
Spatial fraction 
The spatial fraction is used to distinguish between deaths influenced by spatially structured 
factors, and those due to random variation. This parameter estimates the relative contribution 
of the spatial component in the Bayesian spatial survival model, and is defined as: 
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where       is the marginal standard deviation of the spatial component u, and    is the 
standard deviation of the random component v.              
                                                                
Premature deaths 
The number of premature deaths due to spatial inequalities in non-diagnostic factors was 
defined as the total number of deaths within five years of diagnosis that could be avoided, 
i.e.: 
        ∑          
 
                                                            
where    represents the spatial fraction (see equation 4),    represents observed excess 
deaths in the k
th
 stratum (equation 2), and      represents the optimum excess number of 
deaths in the k
th
 stratum (equation 3). 
 
The total number of avoidable premature deaths was calculated as shown in equation 5, and 
was also calculated by stage, distance and area disadvantage categories. The median values of 
the 10,000 MCMC iterations were used as the       value, and 80% credible intervals were 
obtained from the 10
th
 and 90
th
 centiles.  The premature death percentages were calculated by 
dividing Dprem by the observed excess deaths (∑      ).  
 
Results 
The final study cohort consisted of 25,202 females diagnosed with breast cancer and 26,390 
cases of colorectal cancer (14,690 males, 11,700 females) (Table 1), as there were 264 breast 
cancer cases (1.0%) and 280 colorectal cancer cases (1.0%) that did not meet the inclusion 
criteria. 
13 
 
 
Breast cancer 
The unadjusted 5-year relative survival from breast cancer by area disadvantage showed that 
88% of women in the least disadvantaged quintile were likely to survive at least 5 years, 
while for the most disadvantaged quintile this decreased to 83% (Table 1). Survival 
differences by distance to nearest radiation facility were slightly smaller (86% for those 
living less than 2 hours distance, and 83% for those with at least 6 hours travel time).  
 
Breast cancer survival was greatly impacted by stage at diagnosis. Based on DIC values, the 
full model containing age, stage, distance and area disadvantage; the model adjusted for age, 
stage and disadvantage and the model adjusted for age and stage were preferred against the 
alternatives (Table 2). 
 
After adjustment for all factors in the full model, the oldest age group (ages 70-89), advanced 
or unknown stage and increasing area disadvantage had higher risk of death. Notably the 
higher survival observed in the 50-69 compared against the 0-49 age group, as well as the 
impact of distance from nearest radiotherapy treatment facility were no longer evident. 
 
As indicated in Figure 1, even after adjusting for stage there was still moderate evidence for 
spatial inequalities (Tango’s MEET p=0.042 for the model containing age and stage). After 
further adjusting for area disadvantage, spatial survival inequalities were attenuated to non-
significance (p=0.452). 
 
Between 1998 and 2007 there were 2,850 deaths due to breast cancer among women in 
Queensland within five years of diagnosis. After removing the SLAs with a risk of death 
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lower than the 20th centile, there were 2,412 deaths (Table 4). Of these deaths, 170 (7%) 
were estimated to be avoidable if there were no systematic spatial variation in non-diagnostic 
survival components, after adjusting for stage and age at diagnosis. 
 
The proportion of premature deaths was high for those residing more than 2 hours distance 
from a treatment facility, and all area disadvantage quintiles above the least disadvantaged, 
particularly for the most disadvantaged. By stage, most premature deaths were among those 
diagnosed at advanced or unknown stage.  
 
Colorectal cancer 
The unadjusted 5-year relative survival varied by 8 absolute percentage points between the 
least disadvantaged (69%) and most disadvantaged (61%) areas (Table 1). There were also 
survival differences by distance to treatment facilities, with those living within 2 hours 
travelling time having a better survival than those residing a travelling time distance of at 
least 6 hours away (65% versus 60%, respectively).  
 
Among the models considered, the best fit to colorectal cancer survival was the full model 
containing age, sex, stage, distance and area disadvantage as well as the model adjusted for 
age, sex, stage and area disadvantage based on DIC values (Table 3). After adjusting for stage 
at diagnosis, survival remained poorer among older patients and as area disadvantage 
increased. There was also some evidence that survival was poorer among those residing more 
than 6 hours travelling time to treatment, particularly in comparison to those living within 2-6 
hours distance (88% probability that RER is higher).  
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Mapping the stage-adjusted RER did not substantively alter the observed survival inequalities 
(Figure 2), with both models (age and gender only; age, stage and gender) having strong 
evidence of geographical variation (Tango’s MEET p=0.001). Further adjusting for area 
disadvantage and then distance to treatment only slightly reduced the spatial inequalities 
(p=0.004 and p=0.019, respectively). 
 
There were 7,357 deaths due to colorectal cancer within five years of diagnosis in 
Queensland during 1998-2007, and 6,019 deaths after removing the SLAs with a risk of death 
lower than the 20
th
 centile (Table 4). Of these deaths, 470 (8%) deaths would not have 
occurred if there were no spatial inequalities in the non-diagnostic survival component, after 
adjusting for stage, age at diagnosis and gender. There was a clear gradient of a greater 
proportion of premature deaths occurring as distance from radiotherapy treatment facilities 
increased, and also generally as area disadvantage increased. This contrasted with the 
consistency of the proportion of premature deaths across cancer stage categories. 
 
The colorectal cancer stage categories differed from those used for breast cancer stage 
categories. To explore if differences between the cancers may have resulted from different 
stage groupings, analyses were also run using alternate colorectal stage categories (early: 
localized; advanced: non-localized/regional/distant; unknown). Results (not shown) were 
broadly consistent with those reported here. 
 
Discussion 
In this population-based study, cancer stage, age group, and disadvantage were important 
predictors of survival outcomes for people diagnosed with colorectal cancer and women 
diagnosed with breast cancer. After adjusting for stage and excluding the impact of random 
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variation, we estimated that 470 (8%) premature deaths due to colorectal cancer and 170 
(7%) premature deaths due to breast cancer could be attributed to spatial inequalities in 
management factors.  
 
Despite fairly similar numbers of incident cases for colorectal cancer and female breast 
cancer, the lower number of premature deaths attributable to spatial inequalities in 
management factors for breast cancer is due mainly to the higher survival, but also the strong 
influence exerted by stage at diagnosis on breast cancer spatial survival inequalities.  
 
 
A previous study found women living in more remote areas of Queensland were more likely 
to be diagnosed with advanced breast cancer (Baade et al., 2011c). These diagnostic 
inequalities have resulted in survival inequalities, as our study showed the lower survival in 
rural areas was reduced after adjusting for stage. Mammography screening has been shown to 
be effective in diagnosing tumors early (Australian Institute of Health and Welfare, 2010), 
and the current low public mammography participation rate of 57% in the target age group 
(only slightly higher in more regional areas)  (Australian Institute of Health and Welfare, 
2010) provides considerable scope for the spatial survival inequalities resulting from late 
diagnosis to be addressed.  
 
Although geographic differences have been demonstrated in the risk of being diagnosed with 
advanced colon cancer in Queensland (Baade et al., 2011a), we found these spatial 
differences in stage at diagnosis did not exert an important influence on the spatial survival 
inequalities. This is consistent with a previous Australian study which found stage at 
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diagnosis had limited impact on geographical inequalities in colon cancer survival 
inequalities, but more evidence for rectal cancer (Yu et al., 2005b). 
 
Population-based screening would be expected to reduce the stage at which a cancer is 
diagnosed. In Queensland, mammography screening was introduced in 1991 and is freely 
available for women aged 40+ years, with a target age group of 50-69 years. More recently, 
mobile mammography clinics have been used to overcome the barrier of distance for women 
in more remote regions, to the extent that women in rural areas now have higher participation 
rates for public mammography than women in urban areas. Since the screening differential 
(lower screening in urban areas) is the opposite for the stage differential (less advanced stage 
in urban areas), it is unlikely that screening patterns can explain this differential stage 
distribution.  
 
Screening is also an unlikely explanation for the colorectal cancer stage differences.  In 
contrast to breast cancer, there is no population-based screening program for colorectal 
cancer. The Australian bowel cancer screening program (faecal occult blood test) started only 
in 2006, with gradual implementation for adults aged 50, 55 and 65 years of age (Australian 
Institute of Health and Welfare, 2009). 
We found significant evidence that colorectal and breast cancer patients living in areas of 
greater socioeconomic deprivation had lower survival than their counterparts living in more 
affluent areas. This is consistent with other reports (Australian Institute of Health and 
Welfare and Cancer Australia & Australasian Association of Cancer Registries, 2008), 
however, as was the case in our study, it is unclear whether these patterns reflect treatment 
inequalities, or patient characteristics such as obesity, smoking, alcohol consumption and 
comorbidities rather than area-level characteristics (Frederiksen et al., 2009). 
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For breast cancer, stage at diagnosis and area-level disadvantage largely explained the 
survival inequalities, similar to a study in England (Davies et al., 2010).  An American study 
showed much of the socioeconomic inequality in breast cancer survival was explained by 
stage at diagnosis, initial treatment and race (Yu, 2009). In Western Australia, breast cancer 
patients in rural (often lower socioeconomic) areas, were less likely to undergo hormone 
therapy, radiotherapy or be treated by a high-caseload surgeon (Mitchell et al., 2006). These 
treatment inequalities explained the remaining survival differentials in breast cancer after 
adjusting for age and tumor characteristics (Mitchell et al., 2006). 
 
In contrast, colorectal cancer survival inequalities only modestly decreased after adjusting for 
stage, area disadvantage and distance to treatment, suggesting additional factors are 
important. Colorectal cancer survival is influenced by treatment factors such as the type of 
surgery provided, hospital caseload and specialist expertise at the treating institution (Yu et 
al., 2005b). Treatment inequalities may not have been adequately captured, as an American 
study found treatment disparities only slightly reduced after adjusting for socio-demographic 
characteristics and the availability of specialist oncology services (Haas et al., 2011). Further 
investigation to identify factors influencing colorectal cancer spatial inequalities is important. 
 
The higher proportions of premature deaths due to spatial inequalities in non-diagnostic 
factors among the more disadvantaged and distant regions further suggest treatment 
inequalities. Enabling more remote patients to access the same level of treatment and care as 
urban patients is extremely challenging in the Australian environment of very large distances. 
Nonetheless, quantifying the impact of these inequalities will encourage efforts to identify 
ways to reduce these inequalities, leading to substantial public health gains.  
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Our analysis was based on 478 geographical regions, finding that 7.1% and 7.8% of breast 
and colorectal cancer premature deaths respectively were due to spatial inequalities in non-
diagnostic factors. Other studies have tended to use a smaller number of geographical 
regions. One study examined 81 regions across four Nordic countries finding 2.6% of breast 
cancer deaths and 5.0% of colon deaths were considered ‘savable’ if there was no regional 
variation (Dickman et al., 1997). A study in NSW, Australia, after adjusting for broad stage 
categories calculated a similar estimate across 25 regions as 4.4% of breast and 6.9% of colon 
cancer deaths within 5 years of diagnosis (Yu et al., 2004). Our higher percentages could 
reflect the increased potential to detect variability using small geographical areas, or greater 
variability in survival outcomes within Queensland.  
 
Strengths of this study include the high quality, population-based coverage of the Queensland 
Cancer Registry, the ability to adjust for stage at diagnosis, the benefits of analyzing small-
area data using Bayesian hierarchical models and the use of period analysis to provide more 
up-to-date survival estimates. 
 
Limitations include the lack of data on individual socioeconomic characteristics and 
comorbidities, the use of broad rather than clinical stage categories, the substantial proportion 
of cancers with unknown stage at diagnosis, the lack of treatment information and the 
relatively small number of covariates included in the models.  
 
In conclusion, although earlier cancer diagnosis would decrease survival inequalities for 
breast cancer patients in rural areas, there remain an important number of premature deaths 
for breast and colorectal cancer that could be avoided by removing spatial inequalities in non-
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diagnostic factors. Despite a freely available public health service, spatial variation in 
treatment utilization is likely to play an important role, although other environment or 
patient-factors may also be contributing. Identifying the precise non-diagnostic factors that 
cause these premature deaths will not be easy, but unless quantitative data such as these are 
disseminated, there will be little incentive on the part of researchers and health providers to 
investigate, develop and implement the necessary interventions. 
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Appendix: Prior distributions 
 
Prior distributions for α and β were diffuse normal distributions with mean 0 and variance 1.0 
x 10
6
. An intrinsic CAR prior for    was employed to describe local spatial dependence 
across the SLAs, specified as: 
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        (
∑       
∑     
   
  )  
where    = 1 if i, j are adjacent, and 0 otherwise (Besag et al., 1991). As usual, the 
unstructured residual form was modeled with a normal prior,          
  .  
 
The variances    
  and   
   influence the relative weight given to describing residual variation 
through spatial correlation between the estimates or some other (random) source. Since this is 
often unknown, it is typical to place priors on these terms. Commonly the precision (the 
inverse of the variance) is described as a gamma distribution. To examine the impact of the 
selection of distributions for the precision parameters (  and   ) on the  random effect 
components (   and   ), sensitivity analyses were conducted by comparing three 
combinations of gamma distributions (  ) on the precision and 2 combinations of uniform 
distributions (Unif) on the standard deviation:  
1.              ,                
2.               ,                 
3.             ,                   
4.              ,                
5.                ,                  
These gamma distributions have means and variances on the precisions of (10, 1000); (500, 
500000); and for the third option,    has (1,10), while    has (1,1000), respectively. The 
uniform distributions have means and variances on the standard deviations of (5, 8.3) and           
(500, 83333.3). 
 
The priors were evaluated and compared on the basis of summary measures of the posterior 
distribution of the relative excess risk values, DIC values (Spiegelhalter et al., 2002), 
cumulative distribution function plots of the deviance (Aitkin et al., 2009), and convergence 
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diagnostics including trace and density plots as well as the Geweke diagnostic (Geweke, 
1992). On the basis of these, the first option was selected for this study.  
 
 
The model formulation employed for this study has been criticized for potential lack of 
identifiability of the individual u and v components (Eberly and Carlin, 2000). Despite this, it 
is recommended to use the spatial fraction ( ) to determine the relative spatial and random 
effects (Eberly and Carlin, 2000). Leroux et al (2000) proposed an alternative model, where 
only one parameter is included for the spatial/random effects, but the prior on this term acts 
as a mixture distribution incorporating a spatial smoothing parameter λ, where λ provides the 
spatial proportion, similar to our spatial fraction ( ). We found this approach was not feasible 
in this study, as the posterior distribution on λ failed to converge.
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Figure 1: Relative excess risk of death from breast cancer among females in Queensland, 
1998-2007. A) after adjusting for age; B) after adjusting for age and cancer stage at 
diagnosis; C) after adjusting for age, stage and area disadvantage; D) after adjusting for age, 
stage, distance to treatment and area disadvantage. 
Note: The Queensland average RER=1.0 
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Figure 2: Relative excess risk of death from colorectal cancer among persons in Queensland, 
1998-2007. A) after adjusting for age and gender; B) after adjusting for age, gender and 
cancer stage at diagnosis; C) after adjusting for age, gender, stage and area disadvantage; D) 
after adjusting for age, gender, stage, distance to treatment and area disadvantage.  
Note: The Queensland average RER=1.0 
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Table 1: Demographic characteristics of the study population and 5-year survival estimates 
  Colorectal cancer Breast cancer 
Variable 
 
N 
5-year relative 
survival [95% CI] p-value N 
5-year relative 
survival [95% CI] p-value 
Sex 
  
 
  
 
 
Males 14,690 61.2 [60.2, 62.3]  
  
 
 
Females 11,700 67.1 [65.9, 68.3] <0.001 25,202  85.2 [84.5, 85.8]  
Age group 
  
 
  
 
 
0-49 2,067 68.9 [66.5, 71.2]  6,517  85.8 [84.7, 86.7]  
 
50-69 11,525 66.5 [65.4, 67.5]  12,622  87.4 [86.7, 88.1]  
 
70-89 12,798 60.4 [59.1, 61.7] <0.001   6,063  79.4 [77.7, 81.1] <0.001 
Stage 
  
 
  
 
 
Early 12,299 84.6 [83.6, 85.7]  11,505  94.8 [94.1, 95.4]  
 
Advanced 9,672 41.1 [39.8, 42.4]  10,707  80.2 [79.2, 81.2]  
 
Unknown 4,419 54.0 [52.1, 56.0] <0.001  2,990  56.0 [53.5, 58.5] <0.001 
Distance 
  
 
  
 
 
< 2 hours 19,865 64.9 [64.0, 65.8]  19,490  85.7 [85.0, 86.4]  
 
2 – 6 hours 4,554 60.6 [58.7, 62.5]  3,978  83.2 [81.5, 84.7]  
 
6+ hours 1,971 59.7 [56.8, 62.5] <0.001 1,734  83.2 [80.8, 85.5] 0.001 
Area disadvantage 
  
 
  
 
 
Least disadvantaged 3,664 69.0 [66.9, 71.1]  4,098  88.4 [87.0, 89.8]  
 
Less disadvantaged 5,908 64.4 [62.7, 66.1]  5,829  85.4 [84.1, 86.6]  
 
Middle 6,587 64.2 [62.6, 65.8]  6,111  85.0 [83.8, 86.2]  
 
More disadvantaged 6,834 61.7 [60.1, 63.2]  6,189  84.1 [82.8, 85.3]  
 
Most disadvantaged 3,397 60.5 [58.2, 62.7] <0.001 2,975  82.6 [80.7, 84.4] <0.001 
Note: p-values calculated using log-rank test for equality of survivor functions. 
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Table 2: Covariate fixed effects of Relative Excess Risk of death (RER) estimates (80% credible interval) for breast cancer, females 
  Including age 
Including age 
and stage 
Including age 
and distance 
Including age 
and area 
disadvantage 
Including age, 
distance and area 
disadvantage 
Including age, 
stage and area 
disadvantage 
Including age, 
stage, distance and 
area disadvantage 
From the fully 
adjusted model: 
Probability RER 
above preceding 
category (%) 
Fixed effects  
    
 
 
 
Age group       
 
 
 
0-49 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
 
50-69 0.89 (0.84, 0.95) 1.02 (0.95,1.08) 0.89 (0.84, 0.95) 0.89 (0.83,0.94) 0.89 (0.83,0.94) 1.01 (0.95,1.08) 1.01 (0.95,1.08) 58.5 
 
70-89 1.48 (1.37, 1.59) 1.62 (1.51,1.74) 1.48 (1.37, 1.60) 1.46 (1.35,1.57) 1.46 (1.35,1.58) 1.61 (1.49,1.73) 1.61 (1.49,1.73) 100.0 
Stage 
     
 
 
 
 
Early 
 
1.00 
   
1.00 1.00  
 
Advanced 
 
3.34 (3.10,3.61) 
   
3.33 (3.10,3.60) 3.33 (3.08,3.60) 100.0 
 
Unknown 
 
7.93 (7.30,8.65) 
   
7.89 (7.25,8.58) 7.87 (7.23,8.58) 100.0 
Distance 
     
 
 
 
 
< 2 hours 
 
1.00 
 
1.00  1.00  
 
2-6 hours 
 
 1.07 (0.94, 1.20)  1.03 (0.91,1.15)  1.02 (0.91,1.13) 58.4 
 
6+ hours 
 
 1.14 (0.98, 1.31)  1.10 (0.95,1.26)  1.03 (0.90,1.18) 53.9 
Area disadvantage 
     
 
 
 
 
Least disadvantaged 
  
1.00 1.00 1.00 1.00  
 
Less disadvantaged 
  
1.28 (1.16,1.43) 1.29 (1.16,1.43) 1.19 (1.08,1.32) 1.19 (1.08,1.32) 98.8 
 
Middle 
  
 1.27 (1.14,1.42) 1.27(1.14,1.42) 1.17 (1.06,1.31) 1.17 (1.05,1.30) 38.8 
 
More disadvantaged 
  
1.35 (1.20, 1.51) 1.34 (1.20,1.50) 1.23 (1.10,1. 37) 1.21 (1.09,1. 36) 71.7 
 
Most disadvantaged 
  
1.51 (1.33,1.72) 1.50 (1.32,1.71) 1.34 (1.19,1.51) 1.32 (1.17,1.49) 84.6 
         
Spatial fraction 
(80% CrI) 0.57 (0.31,0.80) 0.42 (0.19,0.73) 0.46 (0.19,0.76) 0.37 (0.16,0.68) 0.31 (0.12,0.61) 0.29 (0.11,0.54) 0.29 (0.13,0.57) 
 
DIC 18333.7 17214.1 18337.7 18326.9 18329.6 17212.2 17215.3  
pD 64.2 59.7 63.4 60.6 64.2 61.3 61.9  
Notes:  DIC = Deviance Information Criterion. Smaller values signify a better model fit if the difference is at least 5. 
pD represents the effective number of parameters in the model. Larger values indicate estimates have undergone less smoothing. 
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Table 3: Covariate fixed effects of Relative Excess Risk of death (RER) estimates (80% credible interval) for colorectal cancer, persons 
  
Including age and 
sex 
Including age, 
gender and 
stage 
Including age, 
gender and 
distance 
Including age, 
gender and area 
disadvantage 
Including age,  
gender, distance 
and area 
disadvantage 
Including age, 
stage and area 
disadvantage 
Including age, 
gender, stage, 
distance and area 
disadvantage 
From the fully 
adjusted model: 
Probability RER 
above preceding 
category (%) 
Fixed effects  
    
 
 
 
Sex         
 
Males 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
 
Females 0.94 (0.91, 0.97) 0.96 (0.93, 1.00) 0.94 (0.91, 0.98) 0.95 (0.91, 0.98) 0.95 (0.91, 0.98) 0.96 (0.93, 1.00) 0.97 (0.93, 1.00) 8.5 
Age group 
     
 
 
 
 
0-49 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
 
50-69 1.10 (1.03,1.17) 1.16 (1.09,1.23) 1.09 (1.03,1.16) 1.10 (1.03,1.17) 1.09 (1.03,1.16) 1.15 (1.08,1.22) 1.16 (1.09,1.23) 99.8 
 
70-89 1.49 (1.41, 1.59) 1.72 (1.61,1.83) 1.49 (1.40, 1.58) 1.49 (1.40, 1.59) 1.48 (1.39, 1.58) 1.70 (1.60,1.81) 1.71 (1.61,1.82) 100.0 
Stage 
     
 
 
 
 
Early 
 
1.00 
   
1.00 1.00  
 
Advanced 
 
5.45 (5.21, 5.71) 
   
5.44 (5.20, 5.70) 5.45 (5.21, 5.71) 100.0 
 
Unknown 
 
4.19 (3.96, 4.41) 
   
4.17 (3.96, 4.41) 4.18 (3.96, 4.41) 0.0 
Distance 
     
 
 
 
 
< 2 hours  1.00 
 
1.00  1.00  
 
2-6 hours 
 
 1.06 (0.98, 1.15)  1.05 (0.97, 1.12)  0.99 (0.91,1.06) 42.1 
 
6+ hours  1.09 (0.99, 1.20) 
 
1.08 (0.99, 1.17)  1.07 (0.97,1.16) 87.6 
Area disadvantage 
     
 
 
 
 
Least disadvantaged 
  
1.00 1.00 1.00 1.00  
 
Less disadvantaged 
  
1.15 (1.08, 1.23) 1.16 (1.08, 1.24) 1.12 (1.05,1.20) 1.13 (1.05,1.20) 99.2 
 
Middle 
  
 1.16 (1.09, 1.24) 1.17 (1.09, 1.25) 1.14 (1.07, 1.22) 1.15 (1.07, 1.23) 65.1 
 
More disadvantaged 
  
1.23 (1.15, 1.31) 1.23 (1.15, 1.32) 1.20 (1.12, 1.28) 1.21 (1.13, 1.29) 89.1 
 
Most disadvantaged 
  
1.29 (1.20, 1.39) 1.29 (1.19, 1.39) 1.26 (1.17, 1.36) 1.27 (1.17, 1.37) 83.8 
        
Spatial fraction 
(80% CrI) 0.69 (0.50,0.83) 0.62 (0.43,0.79) 0.60 (0.34,0.81) 0.57 (0.38,0.74) 0.45 (0.24,0.68) 0.52 (0.32,0.71) 0.49 (0.25,0.72) 
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DIC 34660.4 31432.1 34664.6 34651.4 34654.5 31423.4 31425.0  
pD 68.6 65.5 65.0 65.0 63.0 63.9 65.5  
Notes:  DIC = Deviance Information Criterion. Smaller values signify a better model fit if the difference is at least 5. 
pD represents the effective number of parameters in the model. Larger values indicate estimates have undergone less smoothing. 
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Table 4: Premature deaths due to non-diagnostic spatial inequalities after adjusting for age, 
gender and stage at diagnosis among SLAs with a Relative Excess Risk of death above the 
20
th
 centile by stage, distance and area disadvantage categories 
  Observed 
excess 
deaths 
Optimum 
excess 
deaths 
Premature deaths due to non-diagnostic 
spatial inequalities  
(random variation excluded) 
 
Probability % 
premature deaths 
above preceding 
category (%)  
  N [80% CrI] % [80% CrI] 
Colorectal cancer 
      Total 6019 5236 470 [321, 637] 7.8 [5.3, 10.6] 
 Stage 
  
    
 Early 1152 1014 81 [45, 125] 7.0 [3.9, 10.8] 
 Advanced 3571 3099 282 [190, 388] 7.9 [5.3, 10.8] 64.5 
Unknown 1297 1121 104 [65, 149] 8.0 [5, 11.5] 53.1 
Distance 
 
    
 < 2 hours 4066 3637 257 [167, 359] 6.3 [4.1, 8.8] 
 2 - 6 hours 1356 1127 136 [95, 181] 10.1 [7.1, 13.3] 100.0 
6+ hours 619 489 78 [55, 102] 12.8 [9.1, 16.7] 100.0 
Area disadvantage 
 
    
 Least disadvantaged 606 623 0 [0, 4] 0.0 [0.0, 0.6] 
 Less disadvantaged 1218 1088 77 [48, 109] 6.4 [4.0, 9.1] 100.0 
Middle 1413 1245 100 [66, 139] 7.1 [4.6, 9.9] 72.4 
More disadvantaged 1863 1552 185 [129, 247] 10.0 [7.1, 13.1] 99.9 
Most disadvantaged 937 739 120 [85, 157] 12.9 [9.0, 16.8] 100.0 
Breast cancer 
 
    
 Total 2412 1975 170 [86, 307] 7.1 [3.6, 12.7] 
 Stage 
  
    
 Early 414 375 14 [1, 35] 3.4 [0.3, 8.2] 
 Advanced 1339 1069 106 [53, 190] 7.9 [3.9, 14.2] 96.9 
Unknown 659 530 50 [24, 92] 7.6 [3.6, 13.9] 43.5 
Distance 
 
    
 < 2 hours 1731 1453 106 [53, 197] 6.2 [3.1, 11.4] 
2 - 6 hours 469 356 45 [22, 77] 9.6 [4.8, 16.6] 100.0 
6+ hours 221 170 19 [9, 34] 8.9 [4.4, 15.6] 21.4 
Area disadvantage 
 
    
 Least disadvantaged 260 255 1 [0, 10] 0.6 [0.0, 4.0] 
 Less disadvantaged 546 444 39 [19, 71] 7.3 [3.6, 13.0] 100.0 
Middle 598 492 40 [20, 73] 6.8 [3.4, 12.4] 35.1 
More disadvantaged 665 530 52 [26, 94] 7.9 [4.0, 14.0] 87.2 
Most disadvantaged 354 258 38 [19, 66] 10.9 [5.3, 18.7] 99.8 
Notes:  Due to the methodology employed and/or rounding, numbers may not sum to the total. 
Negative numbers of avoidable premature deaths were capped at zero.  
CrI=credible interval. 
 
 
